Skip to main content
. 2022 Jan 25;75(6):975–986. doi: 10.1093/cid/ciac036

Figure 2.

Figure 2.

A, Virologic outcomes at weeks 96 and 144 in the intention-to-treat–exposed (ITT-E) population by the US Food and Drug Administration Snapshot algorithm. B, Adjusted treatment differences (dolutegravir/lamivudine [DTG/3TC] group value − tenofovir alafenamide [TAF] group value), based on Cochran-Mantel-Haenszel stratified analysis, with adjustment for baseline third agent class. Abbreviation: HIV-1, human immunodeficiency virus type 1.